Grainne M. O'Kane

Get full text access Log in, subscribe or purchase for full access. References 1. Dekker, EN ∙ van Dam, JL ∙ Janssen, QP ∙ et al., and the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Improved clinical staging system for localized pancreatic cancer using the ABC factors: a TAPS consortium study J Clin Oncol. 2024; 42:1357-1367 2.

Neoadjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma is not currently recommended as standard practice but can be considered for patients at high risk (eg, high CA19-9, systemic symptoms, or nodal disease) or in a clinical trial.The PRODIGE24/CCTG-PA.6 adjuvant trial demonstrated the longest median overall survival reported to date of 53·5 months (95% CI 43·5–58·4) in a select cohort and documented the importance of completing adjuvant therapy.In the real-world setting, up...

Article Tools REVIEW ARTICLES Special Series: Precision Medicine and Immunotherapy in GI Malignancies Abstract Full Text PDF Figures and Tables Abstract The management of pancreatic ductal adenocarcinoma (PDAC) has posed a considerable challenge for decades, with incidence and mortality rates almost mirroring each other. Despite this, a deeper understanding of the complex biology inherent to PDAC has provided a roadmap for a more precise approach to treatment.